Scheid, C.de Wreede, L.van Biezen, A.Koenecke, C.Gohring, G.Volin, L.Maertens, J.Finke, J.Passweg, J.Beelen, D.Cornelissen, J. J.Itälä-Remes, M.Chevallier, P.Russell, N.Petersen, E.Milpied, N.Espiga, C. RichardPeniket, A.Sierra, J.Mufti, G.Crawley, C.Veelken, J. H.Ljungman, P.Cahn, J. Y.Alessandrino, E. P.de Witte, T.Robin, M.Kroeger, N.2017-11-202017-11-202017-11Scheid, C, de Wreede, L, van Biezen, A, Koenecke, C, Gohring, G, Volin, L, Maertens, J, Finke, J, Passweg, J, Beelen, D, Cornelissen, J J, Itälä-Remes, M, Chevallier, P, Russell, N, Petersen, E, Milpied, N, Espiga, C R, Peniket, A, Sierra, J, Mufti, G, Crawley, C, Veelken, J H, Ljungman, P, Cahn, J Y, Alessandrino, E P, de Witte, T, Robin, M & Kroeger, N 2017, 'Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation : a retrospective analysis of the EBMT chronic malignancies working party', Bone Marrow Transplantation, vol. 52, no. 11, pp. 1519-1525. https://doi.org/10.1038/bmt.2017.171http://hdl.handle.net/10138/228617The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (P <0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (P <0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.7engcc_by_nc_ndinfo:eu-repo/semantics/openAccessPROGNOSTIC SCORING SYSTEMBONE-MARROW-TRANSPLANTATIONACUTE MYELOID-LEUKEMIAMONOSOMAL KARYOTYPEMDSCLASSIFICATIONCYTOGENETICSOUTCOMESSOCIETYCancersArticleopenAccess53dee486-524b-4811-9f29-89f3f23d2ce685032637622000414256900006